Myocardial efficiency during levosimendan infusion in congestive heart failure

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 5, 2000, Pages 522-531

  Ukkonen, Heikki ^a   Saraste, Markku ^a   Akkila, Juha ^b   Knuuti, Juhani ^a   Karanko, Meri ^a   Iida, Hidehiro ^c   Lehikoinen, Pertti ^a   Någren, Kjell ^a   Lehtonen, Lasse ^d   Voipio Pulkki, Liisa Maria ^e  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b ORION CORPORATION   (Finland)

^c RESEARCH INSTITUTE FOR BRAIN AND BLOOD VESSELS AKITA   (Japan)

^d UNIVERSITY OF HELSINKI   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; CARBON 11; LEVOSIMENDAN; OXYGEN 15; PLACEBO; WATER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY VASCULAR RESISTANCE; DOUBLE BLIND PROCEDURE; FEMALE; HEART MUSCLE; HEART MUSCLE BLOOD FLOW; HEART OUTPUT; HEART PERFORMANCE; HEART RIGHT VENTRICLE; HEART STROKE VOLUME; HUMAN; LUNG VASCULAR RESISTANCE; MALE; OXYGEN CONSUMPTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE;

CARDIOTONIC AGENTS; CATHETERIZATION, SWAN-GANZ; CORONARY VESSELS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PYRIDAZINES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033696857     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.110972     Document Type: Article

References (34)

1. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C: A molecular modelling, fluorescense probe and proton nuclear magnetic resonance study
2. Mechanism of action of calcium sensitizing drugs
3. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolymic relaxation in conscious and anesthetized dogs
4. Influence of the novel inotropic agent levosimendan on tension and calcium cycling in failing human myocardium
5. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells
6. Effects of levosimendan on myocardial contractility and oxygen consumption
7. Levosimendan enhances cardiac performance after cardiopulmonary bypass: A prospective, randomized placebo-controlled trial
8. Hemodynamic effects of novel cardiotonic drug simendan: Echocardiographic assessment in healthy volunteers
9. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction
10. Myocardial efficiency during calcium-sensitization with levosimendan: A non-invasive study employing positron emission tomography and echocardiography in healthy volunteers
11. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements
12. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography
13. Left ventricular volumes and ejection fractions by echocardiography
14. The left ventricular end-systolic wall stress-velocity of fiber shortening relation: A load independent index of myocardial contractility
15. Coronary flow reserve is impaired in young men with familial hypercholestrolemia
16. 15O and dynamic positron emission tomography: Strategy for quantification in relation to the partial-volume effect
17. Use of the left ventricular time-activity curve as a noninvasive input function in dynamic oxygen-15-water positron emission tomography
18. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-ll acetate kinetics in patients with dilated cardiomyopathy
19. The two-period change-over design and its use in clinical trial
20. Myocardial energetics in patients with dilated cardiomyopathy. Influence of nitroprusside and enoximone
21. The effects of afterload reduction on myocardial carbon 11-labeled acetate kinetics and noninvasively estimated mechanical efficiency in patients with dilated cardiomyopathy
22. Oxidative metabolism in the myocardium in the in the normal subjects during dobutamine infusion
23. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization
24. Cardiac efficiency
25. Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure: A quantitative assessment by positron emission tomography
26. Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction: Implications for the pathophysiology of chronic myocardial hibernation
27. Pathophysiology of chronic left ventricular dysfunction: New insights from measurement of absolute myocardial blood flow and glucose utilization
28. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting
29. 2 inhalation and positron emission tomography: Theory, error analysis, and application in humans
30. Myocardial blood flow: Comparison of oxygen-15-water bolus injection, slow infusion and oxygen-15-carbon dioxide slow inhalation
31. Assessment of right ventricular oxidative metabolism by positron emission tomography with C-11 acetate in aortic valve disease
32. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure
33. Right ventricular performance and contractile reserve in patients with severe heart failure: Assessment by pressure-area relations and association with outcome